Please use this identifier to cite or link to this item: https://doi.org/10.1007/s00059-012-3719-5
Title: Diastolic heart failure: What we still don't know: Looking for new concepts, diagnostic approaches, and the role of comorbidities
Authors: Tschöpe, C.
Lam, C.S.P. 
Keywords: Diastolic heart failure
Heart failure with preserved ejection fraction (HFPEF)
Heart failure with reduced ejection fraction (HFREF)
Pathophysiology
Therapeutic approaches
Issue Date: Dec-2012
Citation: Tschöpe, C., Lam, C.S.P. (2012-12). Diastolic heart failure: What we still don't know: Looking for new concepts, diagnostic approaches, and the role of comorbidities. Herz 37 (8) : 875-879. ScholarBank@NUS Repository. https://doi.org/10.1007/s00059-012-3719-5
Abstract: Heart failure with preserved ejection fraction (HFPEF) is responsible for half the disease burden of heart failure worldwide, yet there is still much we do not know about this syndrome. Its pathophysiology is classically attributed to diastolic dysfunction (thus "diastolic heart failure"), but accumulating evidence suggests that heterogeneous mechanisms contribute to HFPEF, including systolic abnormalities. Importantly, there remains no proven therapy for HFPEF. To date, clinical trials of neurohormonal blockade have failed to improve outcomes in HFPEF, despite their proven benefits in heart failure with reduced ejection fraction (HFREF). Therefore, it is still an urgent need to better understand the pathophysiology of HFPEF and identify new therapeutic targets. Such potential targets include the myocyte protein titin, intracellular calcium regulation, as well as modulation of the extracellular matrix. We also need to understand why the previous large trials have failed in HFPEF. Are we studying the right patients? How do we best diagnose this syndrome? Are we assessing the appropriate outcomes? Causes of mortality and morbidity differ between HFPEF and HFREF, and the high burden of comorbidities in HFPEF may contribute to noncardiovascular outcomes. Newer therapeutic approaches should be developed with these considerations in mind. In conclusion, HFPEF is still an enigma. New pathophysiological concepts, improved diagnostic strategies, and a better understanding of patient factors are needed to generate new therapeutic options in the future. © 2012 Urban & Vogel.
Source Title: Herz
URI: http://scholarbank.nus.edu.sg/handle/10635/126802
ISSN: 03409937
DOI: 10.1007/s00059-012-3719-5
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

20
checked on Nov 23, 2020

WEB OF SCIENCETM
Citations

20
checked on Nov 23, 2020

Page view(s)

53
checked on Nov 21, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.